BioSpace News Archive

Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has communicated that it has completed patient enrollment for the Hexvix® Phase III bridging trial.

GenScript Biotech Corporation, the world’s leading provider of life-science research tools and services, has expanded its cGMP manufacturing capacity for sgRNA and non-viral DNA payloads with a new, state-of-the-art facility in Zhenjiang, Jiangsu, China.

Caris Life Sciences® announced that the Icahn School of Medicine at Mount Sinai, in New York, NY, has joined the Caris Precision Oncology Alliance™ and will collaborate with Caris on various research projects.

Asieris Pharmaceuticals announced the completion of patient enrollment for its Phase III bridging clinical trial of Hexvix®, a drug used for the diagnosis of bladder cancer.

NanoViricides, Inc. reports that the clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing satisfactorily.

Athira Pharma, Inc. today announced that three poster presentations will be delivered in-person at the upcoming Alzheimer’s Association International Conference (AAIC) 2023, to be held July 16 – 20, 2023, virtually and in Amsterdam, Netherlands.

Mustang Bio, Inc. announced that members of its management team will participate in the 2ndIn Vivo Engineering of Therapeutic Cells Summit, scheduled to take place from July 10-12, 2023, and the 8th Annual CAR-TCR Summit, scheduled to take place from August 29 – September 1, 2023, both in Boston, MA.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a virtual Key Opinion Leader (KOL) webinar on Tuesday, July 11, 2023, at 4:30 p.m. EDT.

PaxMedica, Inc. (Nasdaq: PXMD) and Vox Nova LLC (VoxNova), a privately held corporation, today announced that they have signed an exclusive pharmacy distribution agreement for PaxMedica’s lead pipeline asset, PAX-101.

Allarity Therapeutics, Inc. announced the pricing of its “reasonable best efforts” public offering of 2,444,445 shares of common stock and common warrants to purchase up to 2,444,445 shares of common stock at an effective combined price of $4.50 per share and common warrant for aggregate gross proceeds of approximately $11 million, before deducting placement agent fees and other offering expenses.